Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. arthritis
Show results for
Products
Services
Software
Training
Applications

Companies


Refine by

Arthritis Articles & Analysis

80 news found

Veterinary Therapeutic Antibodies Gain Momentum—Biotech Teams Step Up to Meet Industry Demand

Veterinary Therapeutic Antibodies Gain Momentum—Biotech Teams Step Up to Meet Industry Demand

From Concept to Custom Therapeutics A streamlined pipeline that walks clients through epitope mapping stands as the core of the custom therapeutic antibody development offering, to accommodate antibody discovery, engineering, and production for clients' specific animal model and indication—whether it's generating neutralizing antibodies for viral infections in horses or blocking ...

ByBioVenic


Protheragen-ING Offers a Full Range of Nonsteroidal Anti-inflammatory APIs, Including Celecoxib and Crisaborole

Protheragen-ING Offers a Full Range of Nonsteroidal Anti-inflammatory APIs, Including Celecoxib and Crisaborole

These widely used compounds are helpful to manage various inflammatory conditions such as arthritis, musculoskeletal injuries, toothaches, menstrual pain and headaches. ...

ByProtheragen-ING


Creative Enzymes Introduces S-Adenosyl-L-Homocysteine Hydrolase, Recombinant

Creative Enzymes Introduces S-Adenosyl-L-Homocysteine Hydrolase, Recombinant

Inhibition of this enzyme can produce therapeutic effects in disease states like cancer, rheumatoid arthritis, and cardiovascular disease. Creative Enzymes is known in the enzyme industry for providing a comprehensive range of enzymes, especially for its hydrolases category. ...

ByCreative Enzymes


CD ComputaBio Launches Revolutionary Antibody De Novo Design Service Pioneering Precision Medicine with AI

CD ComputaBio Launches Revolutionary Antibody De Novo Design Service Pioneering Precision Medicine with AI

Autoimmune Diseases: Antibodies are designed to modulate the immune response in conditions like rheumatoid arthritis and multiple sclerosis. 3. Infectious Diseases: Antibodies are developed against rapidly evolving pathogens, such as the influenza virus and SARS-CoV-2. ...

ByCD ComputaBio


Alfa Chemistry Newly Introduces Three APIs to Meet Market Demands: Tofacitinib Citrate, Tamoxifen Citrate, and Epalrestat

Alfa Chemistry Newly Introduces Three APIs to Meet Market Demands: Tofacitinib Citrate, Tamoxifen Citrate, and Epalrestat

Tofacitinib Citrate Tofacitinib Citrate is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It works by suppressing the immune system and reducing inflammation in the body. ...

ByAlfa Chemistry


Galapagos announces changes to Executive Committee

Galapagos announces changes to Executive Committee

Walid joined the company in early 2017 and led it through a critical and transformative phase, including the successful completion of the Phase 3 studies of filgotinib in rheumatoid arthritis and ulcerative colitis. We recognize his important contribution to building out the development organization and to bringing our company to the fully integrated biotech that we are today. ...

ByGalapagos NV


Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors

Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors

“The recommendation by the PRAC reflects the concerns raised by the substance class mainly in older patients with rheumatoid arthritis,” said Dr. Stefan Schreiber, Professor of Medicine and Gastroenterology at the Christian-Albrechts-University in Kiel, Director of the Clinic for Internal Medicine at the University Hospital Schleswig-Holstein and Leader of ...

ByGalapagos NV


Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022

Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022

Walid Abi-Saab, Chief Medical officer, at Galapagos said, “We are excited to present data at ACR which highlights our continued commitment to patients and the healthcare provider community, in particular initial data from our first international, real-world arthritis study. We believe that it’s not only important to control disease activity to prevent long term ...

ByGalapagos NV


Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022

Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022

Our most advanced candidate, SIK3 inhibitor ‘4399, has shown strong preclinical evidence for potential in rheumatoid arthritis (RA) (EULAR 20224), with a promising pharmacological and safety profile. ...

ByGalapagos NV


Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results

Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results

Q3 2022 operational review and recent events Jyseleca commercial & regulatory progress Strong adoption across Europe with reimbursement for rheumatoid arthritis (RA) in 15 countries and for ulcerative colitis (UC) in 10 countries Marketing Authorization Application (MAA) submitted for the treatment of UC to Swissmedic, the regulatory authority in Switzerland Article ...

ByGalapagos NV


GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis

GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis

MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its licensing partner, GSK plc (LSE/NYSE: GSK), provided an update on the ContRAst phase III program for otilimab as a potential treatment of moderate to severe rheumatoid arthritis (RA). The ContRAst phase IIl program enrolled a broad range of difficult-to-treat patients who had an inadequate response to or could not ...

ByMorphoSys AG


What to Expect for an Epidural Injection

What to Expect for an Epidural Injection

If so, you are a candidate for sacroiliac joint pain. Causes include arthritis, pregnancy, traumatic injury, and other infections. If treatment is impossible without surgery, then a sacroiliac fusion may be required, but that’s ultimately at the discretion of the doctor. ...

ByMilestone Scientific, Inc.


HemoShear Therapeutics Advancing Novel Modulators Against Second Target for Horizon Therapeutics’ Gout Discovery Pipeline

HemoShear Therapeutics Advancing Novel Modulators Against Second Target for Horizon Therapeutics’ Gout Discovery Pipeline

Gout is a chronic, progressive inflammatory form of arthritis affecting more than nine million people in the United States that is caused by excess uric acid in the body and needs to be managed aggressively. ...

ByHemoShear Therapeutics, Inc.


INOVIQ carving itself healthy share of multi-billion dollar medical diagnostics market

INOVIQ carving itself healthy share of multi-billion dollar medical diagnostics market

“These messages include DNA, RNA, protein and lipid biomarkers found in blood (or other biofluids) that have important applications in research, diagnosis and treatment for cancer, as well as cardiometabolic diseases like heart attack and diabetes, inflammatory diseases such as rheumatoid arthritis and Crohn’s disease, and neurodegenerative diseases like ...

ByINOVIQ Ltd


Landmark Survey by Stagwell`s The Harris Poll Estimates More Than 72.3 Million U.S. Adults Suffer from Chronic Low Back Pain - Greater than Arthritis, Diabetes, or Heart Disease and with Debilitating Impact on Quality of Life

Landmark Survey by Stagwell`s The Harris Poll Estimates More Than 72.3 Million U.S. Adults Suffer from Chronic Low Back Pain - Greater than Arthritis, Diabetes, or Heart Disease and with Debilitating Impact on Quality of Life

The nationally representative survey estimates that more than 72.3 million U.S. adults – 28% of the adult population – suffer from chronic low back pain (CLBP), higher than previously reported1,2, and greater than arthritis (58.5 million),3 diabetes (37.3 million),4 or heart disease (30.3 million).5 More than three-fourths (76%) say CLBP has interfered with their ...

ByVertos Medical, Inc.


Positive Clinical Results for Bluejay’s Symphony IL-6 Test Presented at AACC 2022

Positive Clinical Results for Bluejay’s Symphony IL-6 Test Presented at AACC 2022

It is mentioned in the presentation that "Dysregulated interleukin-6 (IL-6) levels underlie several pathological conditions, such as sepsis, progression of cancer, rheumatoid arthritis, and many other conditions. Prior studies indicate that high levels of IL-6 serve as an early indication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced hyperinflammation, ...

ByBluejay Diagnostics, Inc.


What Are D-Glucosamines?

What Are D-Glucosamines?

Clinically, active supplementation of glucosamine and chondroitin can relieve the symptoms of arthritis. Therefore, it is widely used to treat osteoarthritis and arthritis pain.D-glucosamine is a monosaccharide containing an amine group instead of a hydroxyl group. ...

ByCD Bioparticles


Former Professional Baseball Player Pain-Free after Knee Surgery with Active Robot Technology Available at INOV8 Surgical

Former Professional Baseball Player Pain-Free after Knee Surgery with Active Robot Technology Available at INOV8 Surgical

Kreuzer, Art Howe most likely had degenerative arthritis in his knee for some time. “Often, people have arthritis for a long time that seems to be well controlled with conservative options such as anti-inflammatory medications,” explains Dr. ...

ByThink Surgical Inc.


Rani Therapeutics Unveils High-Capacity RaniPill Device for Oral Delivery of Biologics

Rani Therapeutics Unveils High-Capacity RaniPill Device for Oral Delivery of Biologics

Rani conducted a preclinical study of RaniPill HC, with each device containing an 18-mg dose of the biologic adalimumab, a tumor necrosis factor (TNF)-α inhibitor that is approved for multiple autoimmune conditions including rheumatoid arthritis and Crohn’s disease. The unencapsulated RaniPill HC device was placed laparoscopically in the jejunum of each of three ...

ByRani Therapeutics


Amgen And Lance Bass Partner To Encourage People To Do A `Double Take` To Recognize The Early Signs Of Psoriatic Arthritis

Amgen And Lance Bass Partner To Encourage People To Do A `Double Take` To Recognize The Early Signs Of Psoriatic Arthritis

THOUSAND OAKS, Calif., May 12, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Otezla® (apremilast) have partnered with pop icon and entrepreneur Lance Bass, for the Double Take campaign to empower people to take action when it comes to psoriatic arthritis. As a singer, dancer and entertainer, Bass understands the importance of staying in tune with your body. Through the ...

ByAmgen Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT